Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability
Abstract Purpose The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform patients about outcomes across different lines of treatment. This retrospective analysis aims to evaluate patient outcome...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Online Access: | https://doi.org/10.1007/s00432-024-05965-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544976652042240 |
|---|---|
| author | Valerie Haller Carina Reiff Rainer Hamacher Karina Kostbade Moritz Kaths Juergen Treckmann Stefanie Bertram Yasmin Zaun Sebastian Bauer Johanna Falkenhorst |
| author_facet | Valerie Haller Carina Reiff Rainer Hamacher Karina Kostbade Moritz Kaths Juergen Treckmann Stefanie Bertram Yasmin Zaun Sebastian Bauer Johanna Falkenhorst |
| author_sort | Valerie Haller |
| collection | DOAJ |
| description | Abstract Purpose The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform patients about outcomes across different lines of treatment. This retrospective analysis aims to evaluate patient outcomes at a large German GIST referral center over the past 15 years. Patients and methods Overall survival (OS) and progression-free survival (PFS) were analyzed in patients with metastatic GIST, with diagnosis of metastases between 2008 and 2021, when at least three lines of treatment were available in Germany (n = 174). Results The median overall survival far exceeds historical data for patients with primary exon 11 and exon 9 mutations (median OS in palliative treatment with imatinib: 7.1 years; median OS in second-line palliative treatment with sunitinib: 2.9 years; median OS in third-line palliative treatment with regorafenib: 1.9 years). Among those patients who received palliative imatinib treatment, no significant difference in median OS survival was observed between those who had received perioperative imatinib for localized disease and those who did not. Furthermore, the location of metastases significantly impacted survival, whereas the time between the initial diagnosis and the diagnosis of metastases had no significant effect on survival. Conclusion In conclusion, this study provides a novel, real-world reference for survival outcomes in patients with metastatic GIST. |
| format | Article |
| id | doaj-art-6a3d81bd47e24e4a88d04d13af029bcb |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-6a3d81bd47e24e4a88d04d13af029bcb2025-01-12T12:06:56ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352024-11-011501111210.1007/s00432-024-05965-2Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availabilityValerie Haller0Carina Reiff1Rainer Hamacher2Karina Kostbade3Moritz Kaths4Juergen Treckmann5Stefanie Bertram6Yasmin Zaun7Sebastian Bauer8Johanna Falkenhorst9Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenGerman Cancer Consortium (DKTK), Partner Site University Hospital EssenGerman Cancer Consortium (DKTK), Partner Site University Hospital EssenGerman Cancer Consortium (DKTK), Partner Site University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenDepartment of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital EssenAbstract Purpose The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform patients about outcomes across different lines of treatment. This retrospective analysis aims to evaluate patient outcomes at a large German GIST referral center over the past 15 years. Patients and methods Overall survival (OS) and progression-free survival (PFS) were analyzed in patients with metastatic GIST, with diagnosis of metastases between 2008 and 2021, when at least three lines of treatment were available in Germany (n = 174). Results The median overall survival far exceeds historical data for patients with primary exon 11 and exon 9 mutations (median OS in palliative treatment with imatinib: 7.1 years; median OS in second-line palliative treatment with sunitinib: 2.9 years; median OS in third-line palliative treatment with regorafenib: 1.9 years). Among those patients who received palliative imatinib treatment, no significant difference in median OS survival was observed between those who had received perioperative imatinib for localized disease and those who did not. Furthermore, the location of metastases significantly impacted survival, whereas the time between the initial diagnosis and the diagnosis of metastases had no significant effect on survival. Conclusion In conclusion, this study provides a novel, real-world reference for survival outcomes in patients with metastatic GIST.https://doi.org/10.1007/s00432-024-05965-2 |
| spellingShingle | Valerie Haller Carina Reiff Rainer Hamacher Karina Kostbade Moritz Kaths Juergen Treckmann Stefanie Bertram Yasmin Zaun Sebastian Bauer Johanna Falkenhorst Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability Journal of Cancer Research and Clinical Oncology |
| title | Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability |
| title_full | Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability |
| title_fullStr | Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability |
| title_full_unstemmed | Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability |
| title_short | Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability |
| title_sort | overall survival of patients with kit mutant metastatic gist in the era of multiple kinase inhibitor availability |
| url | https://doi.org/10.1007/s00432-024-05965-2 |
| work_keys_str_mv | AT valeriehaller overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT carinareiff overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT rainerhamacher overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT karinakostbade overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT moritzkaths overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT juergentreckmann overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT stefaniebertram overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT yasminzaun overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT sebastianbauer overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability AT johannafalkenhorst overallsurvivalofpatientswithkitmutantmetastaticgistintheeraofmultiplekinaseinhibitoravailability |